滚动资讯
IlluminaIs It Time To Reassess Illumina (ILMN) After Its Recent Share Price Volatility? - simplywall.stFierceBiotechGilead cancels midstage HIV trial as FDA’s clinical hold remains intactEndpoints NewsGilead ends a Phase 2/3 trial of long-acting HIV pillsLonza NewsLonza releases annual report - The Vacaville ReporterBioPharma DiveBiogen, on the heels of a $5.6B buyout, turns its sights to early-stage assetsEndpoints NewsNoom plans push into peptides beyond weight loss drugsFierceBiotechThousands of clinical trial sites impacted by Middle East conflict: reportFierceBiotechDrug combo treats multiple cancers with ‘paradox’ mutation in miceFierceBiotechValneva CEO on Pfizer-partnered Lyme vaccine: Why a phase 3 miss doesn’t tell the whole storyAgilentSynthego Welcomes Supreme Court Order Finalizing Invalidation of Agilent CRISPR Patents - PR NewswireEndpoints NewsMaking custom CRISPR therapies could be harder than initially thoughtEndpoints NewsTo counter China, FDA chief wants to speed new drug trial process
Waters 2026年2月10日

沃特世公司(WAT)股价下跌14.5%，尽管第四季度业绩超预期，但2026财年指引令人失望——AlphaStreet新闻

沃特世公司(WAT)股价下跌14.5%，尽管第四季度业绩超预期，但2026财年指引令人失望——AlphaStreet新闻

原文
暂时没有全文，请查看原始来源。

目录

59 全部